Vir Biotechnology Shares Rise 22% as Phase 3 Hepatitis Delta Trial Meets Primary and Secondary Endpoints

Vir Biotechnology, Inc. (NASDAQ:VIR) shares increased 22% on Monday after the company reported that its Phase 3 ECLIPSE 1 clinical trial evaluating elebsiran and tobevibart in adults with chronic hepatitis delta met its primary and key secondary endpoints.

The trial evaluated the investigational combination treatment in 124 patients, including individuals with advanced liver disease, across multiple countries.

At Week 48, 44% of patients receiving the combination achieved undetectable hepatitis delta virus (HDV) levels alongside normalised alanine aminotransferase (ALT) levels, compared with 0% in the delayed-treatment group at Week 12.

The study also met its key secondary endpoint, with 79% of treated patients recording undetectable HDV levels at Week 48, compared with 0% in the delayed-treatment group.

Phase 3 Trial Reports Virologic Responses Across Patient Groups

ECLIPSE 1 enrolled 124 adults with chronic hepatitis delta, randomly assigning participants in a 2:1 ratio to receive monthly subcutaneous injections of elebsiran and tobevibart or delayed treatment.

All patients receiving the combination completed 48 weeks of treatment, with 100% achieving a virologic response at Week 24.

The company reported undetectable HDV RNA levels across patients with and without cirrhosis.

At Week 48, HDV RNA was undetectable in 85% of patients with cirrhosis and 73% of those without cirrhosis.

The results indicate virologic activity across the evaluated patient groups, including individuals with advanced liver disease.

Safety Results Show No Treatment Discontinuations

Vir Biotechnology reported that the combination was generally well tolerated during the study.

One Grade 3 treatment-related adverse event was recorded, while no treatment interruptions or discontinuations were reported.

Most treatment-related adverse events were described as mild to moderate and temporary.

The company said the findings supported the safety profile observed during the clinical development programme.

Additional Phase 2 Data Presented at Liver Disease Conference

Alongside the Phase 3 announcement, Vir Biotechnology released expanded findings from its Phase 2 SOLSTICE trial.

The additional results were presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting in Denver, Colorado.

The presentation included longer-term efficacy and safety data for the elebsiran and tobevibart combination.

The Phase 3 ECLIPSE 1 results provide further clinical evidence for the investigational treatment in chronic hepatitis delta, although the combination remains subject to regulatory review before any potential commercial approval.

Vir Biotechnology stock price